[go: up one dir, main page]

ECSP17021465A - Formulación que comprende glicopirrolato, método y aparato - Google Patents

Formulación que comprende glicopirrolato, método y aparato

Info

Publication number
ECSP17021465A
ECSP17021465A ECIEPI201721465A ECPI201721465A ECSP17021465A EC SP17021465 A ECSP17021465 A EC SP17021465A EC IEPI201721465 A ECIEPI201721465 A EC IEPI201721465A EC PI201721465 A ECPI201721465 A EC PI201721465A EC SP17021465 A ECSP17021465 A EC SP17021465A
Authority
EC
Ecuador
Prior art keywords
glycopyrrolate
magnesium stearate
formulation including
micronized
including glycopyrrolate
Prior art date
Application number
ECIEPI201721465A
Other languages
English (en)
Inventor
Fergus Manford
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51542160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17021465(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of ECSP17021465A publication Critical patent/ECSP17021465A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describe un método para preparar una composición farmacéutica para administración pulmonar que comprende co-micronización de glicopirrolato y estearato de magnesio, en donde el glicopirrolato y el estearato de magnesio co-micronizados se someten posteriormente a una etapa de acondicionamiento que incluye la exposición del glicopirrolato y el estearato de magnesio co- micronizados a la humedad. También se describe una composición hecha por este método.
ECIEPI201721465A 2014-09-09 2017-04-06 Formulación que comprende glicopirrolato, método y aparato ECSP17021465A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14184164 2014-09-09

Publications (1)

Publication Number Publication Date
ECSP17021465A true ECSP17021465A (es) 2017-05-31

Family

ID=51542160

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201721465A ECSP17021465A (es) 2014-09-09 2017-04-06 Formulación que comprende glicopirrolato, método y aparato

Country Status (39)

Country Link
US (2) US10532041B2 (es)
EP (2) EP3191081B1 (es)
JP (1) JP6502501B2 (es)
KR (1) KR101927960B1 (es)
CN (1) CN106604720B (es)
AP (1) AP2017009777A0 (es)
AR (1) AR101793A1 (es)
AU (1) AU2015314272B2 (es)
BR (1) BR112017003888B1 (es)
CA (1) CA2960694C (es)
CL (1) CL2017000560A1 (es)
CO (1) CO2017003056A2 (es)
CY (1) CY1124569T1 (es)
DK (1) DK3191081T3 (es)
DO (1) DOP2017000065A (es)
EA (1) EA037332B1 (es)
EC (1) ECSP17021465A (es)
ES (1) ES2793905T3 (es)
HR (1) HRP20201005T1 (es)
HU (1) HUE049339T2 (es)
IL (1) IL250427A0 (es)
LT (1) LT3191081T (es)
MA (2) MA50680A (es)
MX (1) MX373939B (es)
MY (1) MY181647A (es)
NZ (1) NZ728435A (es)
PH (1) PH12017500303B1 (es)
PL (1) PL3191081T3 (es)
PT (1) PT3191081T (es)
RS (1) RS60299B1 (es)
SG (1) SG11201700536XA (es)
SI (1) SI3191081T1 (es)
SM (1) SMT202000280T1 (es)
SV (1) SV2017005403A (es)
TN (1) TN2017000077A1 (es)
TW (1) TWI602566B (es)
UA (1) UA115958C2 (es)
WO (1) WO2016038116A1 (es)
ZA (1) ZA201700658B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3009923T3 (en) 2017-03-15 2025-03-31 Vectura Ltd Method and formulation
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN116194087B (zh) * 2020-01-15 2025-07-11 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
CN116115590B (zh) * 2023-01-17 2025-12-05 上海方予健康医药科技有限公司 一种用于制备吸入粉雾剂的方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
CA2404645A1 (en) 2000-04-11 2001-10-18 Elan Pharmaceuticals, Inc. Physically stabilized dry powder formulations
WO2002008470A1 (en) 2000-07-20 2002-01-31 Campina B.V. Method for producing a crystalline tableting additive, additive thus obtained and use thereof
AU2211502A (en) 2000-11-30 2002-06-11 Vectura Ltd Method of making particles for use in a pharmaceutical composition
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7188993B1 (en) * 2003-01-27 2007-03-13 Harold W Howe Apparatus and method for resonant-vibratory mixing
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060292077A1 (en) 2005-03-18 2006-12-28 Zhao Jonathon Z Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US8074906B2 (en) 2005-07-07 2011-12-13 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
JP5283835B2 (ja) * 2006-07-06 2013-09-04 東京エレクトロン株式会社 マイクロ波プラズマ処理装置及びマイクロ波プラズマ処理装置用ゲートバルブ
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
EP2217278A1 (en) 2007-11-07 2010-08-18 AstraZeneca AB Dry powder formulations comprising ascorbic acid derivates
ES2460576T3 (es) 2007-12-13 2014-05-13 Novartis Ag Procedimiento para preparar una sustancia farmacológica en partículas y cristalina
KR20100099281A (ko) 2007-12-13 2010-09-10 노파르티스 아게 유기 화합물
US8235314B2 (en) 2009-02-12 2012-08-07 Linde Aktiengesellschaft Nonequilibrium humidity control for jet milling
RU2554878C2 (ru) 2009-04-09 2015-06-27 Новартис Аг Способ получения солей пирролидиния
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
WO2011120779A1 (en) * 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
WO2011131663A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. "process for providing particles with reduced electrostatic charges"
EP2611423B2 (en) 2010-08-31 2022-09-21 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
JP2014505717A (ja) 2011-02-17 2014-03-06 シプラ・リミテッド 医薬組成物
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
RU2013155903A (ru) 2011-05-17 2015-06-27 Перл Терапьютикс, Инк. Композиции, способы и устройства для респираторной доставки двух или более активных средств
GB201205632D0 (en) 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
US20150202148A1 (en) 2012-07-05 2015-07-23 Arven llac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
EA201590030A1 (ru) 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
DE102012211907A1 (de) * 2012-07-09 2014-01-09 Robert Bosch Gmbh Drehschlagschrauber mit einem Schlagwerk
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
MX2015016058A (es) 2013-05-22 2016-12-20 Pearl Therapeutics Inc Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos.
US20160317391A1 (en) 2013-12-17 2016-11-03 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants

Also Published As

Publication number Publication date
CY1124569T1 (el) 2022-03-24
PH12017500303A1 (en) 2017-07-03
NZ728435A (en) 2017-11-24
RS60299B1 (sr) 2020-07-31
US20170258762A1 (en) 2017-09-14
LT3191081T (lt) 2020-07-10
ES2793905T3 (es) 2020-11-17
EA201790544A1 (ru) 2017-09-29
US10532041B2 (en) 2020-01-14
UA115958C2 (uk) 2018-01-10
ZA201700658B (en) 2022-05-25
EP3191081A1 (en) 2017-07-19
SG11201700536XA (en) 2017-02-27
CN106604720A (zh) 2017-04-26
KR20170054458A (ko) 2017-05-17
JP2017527621A (ja) 2017-09-21
MY181647A (en) 2020-12-30
AR101793A1 (es) 2017-01-11
MX373939B (es) 2020-07-10
CL2017000560A1 (es) 2018-03-16
DOP2017000065A (es) 2017-07-15
EA037332B1 (ru) 2021-03-15
MX2017003080A (es) 2017-11-15
EP3191081B1 (en) 2020-03-25
AP2017009777A0 (en) 2017-03-31
AU2015314272A1 (en) 2017-02-09
MA40617A (fr) 2017-07-19
US20200155506A1 (en) 2020-05-21
SI3191081T1 (sl) 2020-07-31
PT3191081T (pt) 2020-05-29
CO2017003056A2 (es) 2017-07-11
PH12017500303B1 (en) 2021-03-31
TWI602566B (zh) 2017-10-21
WO2016038116A1 (en) 2016-03-17
CN106604720B (zh) 2020-03-10
EP3689332B1 (en) 2026-01-07
EP3689332A1 (en) 2020-08-05
DK3191081T3 (da) 2020-06-15
BR112017003888B1 (pt) 2022-11-16
HUE049339T2 (hu) 2020-09-28
MA40617B1 (fr) 2020-05-29
CA2960694C (en) 2021-05-04
IL250427A0 (en) 2017-03-30
MA50680A (fr) 2020-08-05
CA2960694A1 (en) 2016-03-17
SMT202000280T1 (it) 2020-07-08
PL3191081T3 (pl) 2020-09-07
TW201617072A (zh) 2016-05-16
SV2017005403A (es) 2017-08-23
AU2015314272B2 (en) 2017-11-23
JP6502501B2 (ja) 2019-04-17
KR101927960B1 (ko) 2018-12-11
TN2017000077A1 (en) 2018-07-04
BR112017003888A2 (pt) 2018-01-23
HRP20201005T1 (hr) 2020-10-16

Similar Documents

Publication Publication Date Title
CL2020002269A1 (es) Anticuerpo que se une a redil33; polinucleótido; vector; célula hospedadora; método para producir el anticuerpo; composición farmacéutica; producto de combinación; uso del anticuerpo para tratar una afección inflamatoria (divisional de la solicitud no. 201702433)
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
IL249061B (en) Combination, composition, and method of administering the combination or composition to animals
LT3674298T (lt) Pakeistieji indazolai, jų gavimo būdas, juos turinčios farmacinės kompozicijos ir jų panaudojimas vaistų gamybai
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CO2017002472A2 (es) Formulación de acetato de abiraterona
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
HK1243636A1 (zh) 用於治疗代谢疾病和癌症的新的线粒体解偶联剂
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
ECSP17021465A (es) Formulación que comprende glicopirrolato, método y aparato
MX2017004312A (es) Composicion farmaceutica oral de baja dosis de isotretinoina.
MX387903B (es) Proceso para la preparacion de acidos 3-hidroxipicolinicos.
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
CL2019003571A1 (es) Lipido que comprende ácido docosapentanoico. (divisional solicitud 3351-2016)
MX2017008373A (es) Compuestos, composiciones y metodos.
BR112017009848A2 (pt) combinação, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica.
HUE049284T2 (hu) Eljárás (S)-2-acetiloxipropionsav és származékai elõállítására
ES2501367B1 (es) Método de tratamiento de coccidiosis
FR3026009B1 (fr) Nanocapsules lipidiques, compositions pharmaceutiques, procede de preparation, et utilisations correspondants
PT2933251T (pt) Composição farmacêutica que pode ser utilizada para o tratamento de uma patologia do pé de um mamífero ungulado
ECSP16086746A (es) Formulación inmunosupresora
PE20151500A1 (es) 4-(4-ciano-2-tioaril) dihidropirimidinonas y su uso
BR112018009807A2 (pt) processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico